HEALTH PROFESSIONAL · SOURCE READING

Treatment options under clinical evaluation

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Accepted Risk-Adapted Treatment Strategies / Classical Hodgkin lymphoma, high-risk disease

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Source links and citations

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

AHOD2131 (NCT05675410) (A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab): This trial compares immunotherapy (brentuximab vedotin and nivolumab) with standard treatment alone for patients with stage I and stage II classic Hodgkin lymphoma.

Source links and citations

AHOD2131 (NCT05675410)

Studies cited in this source section

Source citation is not a determination that a study applies to you.

NCT05675410 · design, results and side effects

Preserved source evidence · Not medical advice